2 terminated, 1 completed. 3 Phase 3.
| Phase | Trials | Status |
|---|---|---|
| Phase 3 | 3 | Terminated 2, Completed 1 |
Follow Simufilam: new trials by email Literature Review of Simufilam trials Research Report on Simufilam
Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.
| Trial | Phase | Status | Sponsor | Enrollment | Start | Updated |
|---|---|---|---|---|---|---|
| Open-label Extension for Phase 3 Clinical Trials of Simufilam Simufilam - Alzheimer Disease | Phase 3 | Terminated | Cassava Sciences, Inc. | 1081 | 2022-11-07 | 2025-05-23 |
| Simufilam 50 mg or 100 mg for Mild-to-Moderate Alzheimer's Disease Simufilam, Placebo - Alzheimer Disease | Phase 3 | Terminated | Cassava Sciences, Inc. | 1125 | 2021-11-18 | 2025-09-22 |
| Simufilam 100 mg for Mild-to-Moderate Alzheimer's Disease Simufilam, Placebo - Alzheimer Disease | Phase 3 | Completed | Cassava Sciences, Inc. | 804 | 2021-11-03 | 2025-05-25 |
Canada (3) · United States (3) · Australia (2) · Puerto Rico (2) · South Korea (2)
James Kupiec, MD (3)